GlaxoSmithKline announced that in patients with platinum-resistant ovarian cancer, the median progression-free survival with Morez therapy reached 11.1 months. GlaxoSmithKline also announced that in ovarian cancer trials, the objective remission rate confirmed by Moretz therapy was 62%, with a median remission duration of 12.2 months.

Zhitongcaijing · 4d ago
GlaxoSmithKline announced that among patients with platinum-resistant ovarian cancer, the median progression-free survival with Morez therapy reached 11.1 months. GlaxoSmithKline also announced that in ovarian cancer trials, the objective remission rate confirmed by Moretz therapy was 62%, with a median remission duration of 12.2 months.